#SARSCoV2 mRNA vaccine development enabled by prototype pathogen preparedness
 3791 Saturday, 13 June, 2020, 18:35 A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation. |
How many potentially hazardous asteroids approach Earth?
602Yesterday, 22:50
Granite sliding on granite: friction, wear rates, surface topography, and the scale-dependence of rate–state effects
112913.04.2026, 02:15
Ancient alphabets, new insights: Researchers uncover hidden links among the letters
126212.04.2026, 22:02
Archaeologists have discovered an ancient Roman bridge in Zaragoza. (photo)
287907.04.2026, 00:08
What Archaeologists Found While Searching for a Buried Second Sphinx in Egypt
235506.04.2026, 00:33
Astronauts arrive at launch pad for first crewed mission around Moon in more than 50 years (video)
280301.04.2026, 22:38
NASA set for first crewed moon return in over half a century (video)
271801.04.2026, 13:49
The Last Bastion of the Hominins: Deciphering the 40,000-Year Sealed Silence of Gibraltar (photo, video)
621719.03.2026, 23:42